FDA Renews Blood Products Advisory Committee Through 2028
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The notice keeps the FDA's Blood Products Advisory Committee in place for another two years, with a new charter running until May 13, 2028. The committee gives FDA expert advice on blood, blood-derived products, donor screening, product labeling, clinical studies, biological product licenses, and related medical devices. The practical impact is limited but relevant for blood establishments, biotech and biologics companies, medical device makers, hospitals, researchers, and patient or consumer groups. No immediate compliance duty changes, but the committee will continue shaping FDA decisions and guidance in this area.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Renews the FDA Blood Products Advisory Committee for two additional years
- Sets the new committee charter to expire on May 13, 2028
- Confirms the committee will continue advising FDA on blood products, donor screening, labeling, licenses, and related device issues